全球艾滋病毒/艾滋病疫苗企业：科学战略计划。
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.
出版信息
PLoS Med. 2005 Feb;2(2):e25. doi: 10.1371/journal.pmed.0020025. Epub 2005 Jan 18.
Abstract
The development of an HIV vaccine remains one of the most difficult challenges confronting biomedical research today. A new international collaboration shares its plan to address the challenge
摘要
开发艾滋病病毒疫苗仍然是当今生物医学研究面临的最艰巨挑战之一。一个新的国际合作团队分享了应对这一挑战的计划。
相似文献
1
The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.
PLoS Med. 2005 Feb;2(2):e25. doi: 10.1371/journal.pmed.0020025. Epub 2005 Jan 18.
2
The global HIV vaccine enterprise.
Int Microbiol. 2005 Jun;8(2):93-101.
3
The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise.
Nat Med. 2010 Sep;16(9):981-9. doi: 10.1038/nm0910-981.
4
The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.
Curr Opin HIV AIDS. 2010 Sep;5(5):414-20. doi: 10.1097/COH.0b013e32833cfe32.
5
Expanding research capacity and accelerating AIDS vaccine development in Asia.
Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):766-84.
6
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.
Curr Opin HIV AIDS. 2010 Sep;5(5):435-52. doi: 10.1097/COH.0b013e32833c95c1.
7
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.
PLoS Med. 2010 Sep 21;7(9):e1000331. doi: 10.1371/journal.pmed.1000331.
8
The enterprise changes course.
IAVI Rep. 2011 Sep-Oct;15(5):9-13.
9
A transformed global enterprise for an HIV vaccine.
J Int AIDS Soc. 2021 Nov;24 Suppl 7(Suppl 7):e25822. doi: 10.1002/jia2.25822.
10
Grappling with global concerns in the search for an HIV vaccine.
J Assoc Nurses AIDS Care. 1999 Jan-Feb;10(1):17-20. doi: 10.1016/S1055-3290(06)60228-8.
引用本文的文献
1
A transformed global enterprise for an HIV vaccine.
J Int AIDS Soc. 2021 Nov;24 Suppl 7(Suppl 7):e25822. doi: 10.1002/jia2.25822.
2
Organizing the HIV vaccine development effort.
Curr Opin HIV AIDS. 2013 Sep;8(5):369-75. doi: 10.1097/COH.0b013e328363f5b6.
3
Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.
BMC Bioinformatics. 2013 Apr 30;14:145. doi: 10.1186/1471-2105-14-145.
4
Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.
J Virol. 2013 Jun;87(11):6137-49. doi: 10.1128/JVI.00178-13. Epub 2013 Mar 20.
5
Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239.
J Virol. 2013 Jan;87(1):433-43. doi: 10.1128/JVI.01746-12. Epub 2012 Oct 24.
6
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
PLoS One. 2012;7(1):e30963. doi: 10.1371/journal.pone.0030963. Epub 2012 Jan 27.
7
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.
J Immunol Methods. 2012 Jan 31;375(1-2):57-67. doi: 10.1016/j.jim.2011.09.007. Epub 2011 Sep 22.
8
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.
Retrovirology. 2011 Jul 7;8:54. doi: 10.1186/1742-4690-8-54.
9
LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays.
BMC Immunol. 2011 May 27;12:33. doi: 10.1186/1471-2172-12-33.
10
LabKey Server: an open source platform for scientific data integration, analysis and collaboration.
BMC Bioinformatics. 2011 Mar 9;12:71. doi: 10.1186/1471-2105-12-71.
本文引用的文献
1
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
Nat Med. 2004 Aug;10(8):806-10. doi: 10.1038/nm0804-806.
2
Urgently needed: a filter for the HIV-1 vaccine pipeline.
Nat Med. 2004 Aug;10(8):769-71. doi: 10.1038/nm0804-769.
3
HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?
Lancet. 2004;364(9428):10-1. doi: 10.1016/S0140-6736(04)16609-9.
4
Modulating vaccine responses with dendritic cells and Toll-like receptors.
Immunol Rev. 2004 Jun;199:227-50. doi: 10.1111/j.0105-2896.2004.00144.x.
5
AIDS vaccines. G8 leaders endorse global effort.
Science. 2004 Jun 18;304(5678):1728. doi: 10.1126/science.304.5678.1728b.
6
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
J Virol. 2004 Jul;78(13):7069-78. doi: 10.1128/JVI.78.13.7069-7078.2004.
7
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
J Immunol. 2004 May 15;172(10):6290-7. doi: 10.4049/jimmunol.172.10.6290.
8
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Science. 2004 Mar 26;303(5666):2019-22. doi: 10.1126/science.1093137.
9
The mucosal immune system and HIV-1 infection.
AIDS Rev. 2003 Oct-Dec;5(4):245-52.
10
Prospects for an AIDS vaccine.
Nat Med. 2004 Mar;10(3):221-3. doi: 10.1038/nm0304-221.
Zotero 插件